Advancing (89)Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential

The accelerated approval of the monoclonal antibody (mAb) aducanumab as a treatment option for Alzheimer's Disease and the continued discussions about its efficacy have shown that a better understanding of immunotherapy for the treatment of neurodegenerative diseases is needed. (89)Zr-immuno-PE...

Descripción completa

Detalles Bibliográficos
Autores principales: Wuensche, Thomas E., Stergiou, Natascha, Mes, Iris, Verlaan, Mariska, Schreurs, Maxime, Kooijman, Esther J. M., Janssen, Bart, Windhorst, Albert D., Jensen, Allan, Asuni, Ayodeji A., Bang-Andersen, Benny, Beaino, Wissam, van Dongen, Guus A. M. S., Vugts, Danielle J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576608/
https://www.ncbi.nlm.nih.gov/pubmed/36276653
http://dx.doi.org/10.7150/thno.73509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576608/
https://www.ncbi.nlm.nih.gov/pubmed/36276653
http://dx.doi.org/10.7150/thno.73509

Ejemplares similares